Pharmacophore-based small molecule CXCR4 ligands

Area of Science:

• Medicinal Chemistry
• Virology
• Molecular Biology

Background:

• The C-X-C chemokine receptor type 4 (CXCR4) is a key target for HIV therapy.
• Peptide T140 is a known potent antagonist of CXCR4.
• Developing small molecule CXCR4 ligands offers potential therapeutic advantages.

Purpose of the Study:

• To design and synthesize novel low molecular weight CXCR4 ligands.
• To evaluate the CXCR4-binding affinity and anti-HIV activity of these compounds.
• To elucidate the structure-activity relationships (SAR) of key pharmacophores for CXCR4 interaction.

Main Methods:

• Peptide-based drug design utilizing the T140 scaffold.
• Synthesis of novel compounds incorporating naphthyl, fluorobenzyl, and pyridyl moieties.
• In vitro assays to assess CXCR4 binding and anti-HIV efficacy.

Main Results:

• Several novel low molecular weight compounds exhibited significant CXCR4-binding activity.
• Compounds demonstrated potent anti-HIV activity in vitro.
• Specific structural features of naphthyl, fluorobenzyl, and pyridyl groups essential for CXCR4 binding were identified.

Conclusions:

• The study successfully identified potent CXCR4 ligands with anti-HIV potential.
• Defined SAR provides insights into the molecular recognition of CXCR4.
• Discovery of ligands with dual recognition modes expands therapeutic strategies against HIV.